▶ 調査レポート

非小細胞肺がん治療薬の世界市場 2020年:企業別・地域別・種類別・用途別市場予測

• 英文タイトル:Global Drugs for Non-small Cell Lung Cancer Market 2020 by Company, Regions, Type and Application, Forecast to 2025
• レポートコード:D0804-15818
• 出版社/出版日:GlobalInfoResearch / 2020年7月28日
• レポート形態:英文、PDF、141ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥480,240 (USD3,480)▷ お問い合わせ
  Multi User¥720,360 (USD5,220)▷ お問い合わせ
  Corporate User¥960,480 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、非小細胞肺がん治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。非小細胞肺がん治療薬の種類別市場規模(高周波アブレーション(RFA)、放射線療法、化学療法、標的療法、免疫療法)、用途別市場規模(病院、クリニック、その他)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):Bristol-Myers Squibb、Apotex、Sanofi、GlaxoSmithKline、Amgen、Menarini、CellAct Pharma、Alchemia、Ziopharm Oncology、BioMarin Pharmaceutical、CytRx、Fresenius Kabi、Cerulean Pharma、Hikma Pharmaceuticals、Eli Lilly、Curis、Cipla、Genentech、Exelixis、Cornerstone Pharmaceuticals、Hospira、Ligand Pharmaceuticals、Kyowa Hakko Kirin、Intas Pharmaceuticals、Karyopharm Therapeutics
・地域別グローバル市場分析 2015年-2020年
・非小細胞肺がん治療薬の北米市場(アメリカ、カナダ、メキシコ)
・非小細胞肺がん治療薬のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・非小細胞肺がん治療薬のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・非小細胞肺がん治療薬の南米市場(ブラジル、アルゼンチン)
・非小細胞肺がん治療薬の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:高周波アブレーション(RFA)、放射線療法、化学療法、標的療法、免疫療法
・用途別分析:病院、クリニック、その他
・地域別市場規模予測 2021年-2025年
・調査の結果・結論

Market Overview
The global Drugs for Non-small Cell Lung Cancer market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Drugs for Non-small Cell Lung Cancer market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Drugs for Non-small Cell Lung Cancer market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Drugs for Non-small Cell Lung Cancer market has been segmented into:
Radiofrequency Ablation (RFA)
Radiation Therapy
Chemotherapy
Targeted Therapies
Immunotherapy

By Application, Drugs for Non-small Cell Lung Cancer has been segmented into:
Hospitals
Clinics
Other

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Drugs for Non-small Cell Lung Cancer market presented in the report. This section sheds light on the sales growth of different regional and country-level Drugs for Non-small Cell Lung Cancer markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Drugs for Non-small Cell Lung Cancer market.

The report offers in-depth assessment of the growth and other aspects of the Drugs for Non-small Cell Lung Cancer market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Drugs for Non-small Cell Lung Cancer Market Share Analysis
Drugs for Non-small Cell Lung Cancer competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Drugs for Non-small Cell Lung Cancer sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Drugs for Non-small Cell Lung Cancer sales, revenue and market share for each player covered in this report.

The major players covered in Drugs for Non-small Cell Lung Cancer are:
Bristol-Myers Squibb
Apotex
Sanofi
GlaxoSmithKline
Amgen
Menarini
CellAct Pharma
Alchemia
Ziopharm Oncology
BioMarin Pharmaceutical
CytRx
Fresenius Kabi
Cerulean Pharma
Hikma Pharmaceuticals
Eli Lilly
Curis
Cipla
Genentech
Exelixis
Cornerstone Pharmaceuticals
Hospira
Ligand Pharmaceuticals
Kyowa Hakko Kirin
Intas Pharmaceuticals
Karyopharm Therapeutics

レポート目次

Table of Contents

1 Drugs for Non-small Cell Lung Cancer Market Overview
1.1 Product Overview and Scope of Drugs for Non-small Cell Lung Cancer
1.2 Classification of Drugs for Non-small Cell Lung Cancer by Type
1.2.1 Global Drugs for Non-small Cell Lung Cancer Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type in 2019
1.2.3 Radiofrequency Ablation (RFA)
1.2.4 Radiation Therapy
1.2.5 Chemotherapy
1.2.6 Targeted Therapies
1.2.7 Immunotherapy
1.3 Global Drugs for Non-small Cell Lung Cancer Market by Application
1.3.1 Overview: Global Drugs for Non-small Cell Lung Cancer Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Drugs for Non-small Cell Lung Cancer Market by Regions
1.4.1 Global Drugs for Non-small Cell Lung Cancer Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Drugs for Non-small Cell Lung Cancer (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Drugs for Non-small Cell Lung Cancer Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Drugs for Non-small Cell Lung Cancer Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Drugs for Non-small Cell Lung Cancer Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Drugs for Non-small Cell Lung Cancer Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Drugs for Non-small Cell Lung Cancer Status and Prospect (2015-2025)
2 Company Profiles
2.1 Bristol-Myers Squibb
2.1.1 Bristol-Myers Squibb Details
2.1.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Bristol-Myers Squibb SWOT Analysis
2.1.4 Bristol-Myers Squibb Product and Services
2.1.5 Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.2 Apotex
2.2.1 Apotex Details
2.2.2 Apotex Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Apotex SWOT Analysis
2.2.4 Apotex Product and Services
2.2.5 Apotex Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Sanofi SWOT Analysis
2.3.4 Sanofi Product and Services
2.3.5 Sanofi Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 GlaxoSmithKline SWOT Analysis
2.4.4 GlaxoSmithKline Product and Services
2.4.5 GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Amgen SWOT Analysis
2.5.4 Amgen Product and Services
2.5.5 Amgen Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.6 Menarini
2.6.1 Menarini Details
2.6.2 Menarini Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Menarini SWOT Analysis
2.6.4 Menarini Product and Services
2.6.5 Menarini Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.7 CellAct Pharma
2.7.1 CellAct Pharma Details
2.7.2 CellAct Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 CellAct Pharma SWOT Analysis
2.7.4 CellAct Pharma Product and Services
2.7.5 CellAct Pharma Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.8 Alchemia
2.8.1 Alchemia Details
2.8.2 Alchemia Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Alchemia SWOT Analysis
2.8.4 Alchemia Product and Services
2.8.5 Alchemia Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.9 Ziopharm Oncology
2.9.1 Ziopharm Oncology Details
2.9.2 Ziopharm Oncology Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Ziopharm Oncology SWOT Analysis
2.9.4 Ziopharm Oncology Product and Services
2.9.5 Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.10 BioMarin Pharmaceutical
2.10.1 BioMarin Pharmaceutical Details
2.10.2 BioMarin Pharmaceutical Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 BioMarin Pharmaceutical SWOT Analysis
2.10.4 BioMarin Pharmaceutical Product and Services
2.10.5 BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.11 CytRx
2.11.1 CytRx Details
2.11.2 CytRx Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 CytRx SWOT Analysis
2.11.4 CytRx Product and Services
2.11.5 CytRx Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.12 Fresenius Kabi
2.12.1 Fresenius Kabi Details
2.12.2 Fresenius Kabi Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 Fresenius Kabi SWOT Analysis
2.12.4 Fresenius Kabi Product and Services
2.12.5 Fresenius Kabi Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.13 Cerulean Pharma
2.13.1 Cerulean Pharma Details
2.13.2 Cerulean Pharma Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Cerulean Pharma SWOT Analysis
2.13.4 Cerulean Pharma Product and Services
2.13.5 Cerulean Pharma Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.14 Hikma Pharmaceuticals
2.14.1 Hikma Pharmaceuticals Details
2.14.2 Hikma Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Hikma Pharmaceuticals SWOT Analysis
2.14.4 Hikma Pharmaceuticals Product and Services
2.14.5 Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.15 Eli Lilly
2.15.1 Eli Lilly Details
2.15.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Eli Lilly SWOT Analysis
2.15.4 Eli Lilly Product and Services
2.15.5 Eli Lilly Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.16 Curis
2.16.1 Curis Details
2.16.2 Curis Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 Curis SWOT Analysis
2.16.4 Curis Product and Services
2.16.5 Curis Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.17 Cipla
2.17.1 Cipla Details
2.17.2 Cipla Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Cipla SWOT Analysis
2.17.4 Cipla Product and Services
2.17.5 Cipla Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.18 Genentech
2.18.1 Genentech Details
2.18.2 Genentech Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Genentech SWOT Analysis
2.18.4 Genentech Product and Services
2.18.3 Genentech Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.19 Exelixis
2.19.1 Exelixis Details
2.19.2 Exelixis Major Business and Total Revenue (Financial Highlights) Analysis
2.19.3 Exelixis SWOT Analysis
2.19.4 Exelixis Product and Services
2.19.5 Exelixis Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.20 Cornerstone Pharmaceuticals
2.20.1 Cornerstone Pharmaceuticals Details
2.20.2 Cornerstone Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.20.3 Cornerstone Pharmaceuticals SWOT Analysis
2.20.4 Cornerstone Pharmaceuticals Product and Services
2.20.5 Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.21 Hospira
2.21.1 Hospira Details
2.21.2 Hospira Major Business and Total Revenue (Financial Highlights) Analysis
2.21.3 Hospira SWOT Analysis
2.21.4 Hospira Product and Services
2.21.5 Hospira Drugs for Non-small Cell Lung Cancer Revenue, Gross Margin and Market Share (2018-2019)
2.22 Ligand Pharmaceuticals
2.23 Kyowa Hakko Kirin
2.24 Intas Pharmaceuticals
2.25 Karyopharm Therapeutics
3 Market Competition, by Players
3.1 Global Drugs for Non-small Cell Lung Cancer Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Drugs for Non-small Cell Lung Cancer Players Market Share
3.2.2 Top 10 Drugs for Non-small Cell Lung Cancer Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Drugs for Non-small Cell Lung Cancer Revenue and Market Share by Regions
4.2 North America Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
4.3 Europe Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
4.5 South America Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
5 North America Drugs for Non-small Cell Lung Cancer Revenue by Countries
5.1 North America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
5.2 USA Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
5.3 Canada Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
5.4 Mexico Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
6 Europe Drugs for Non-small Cell Lung Cancer Revenue by Countries
6.1 Europe Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
6.2 Germany Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
6.3 UK Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
6.4 France Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
6.5 Russia Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
6.6 Italy Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue by Countries
7.1 Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
7.2 China Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
7.3 Japan Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
7.4 Korea Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
7.5 India Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
8 South America Drugs for Non-small Cell Lung Cancer Revenue by Countries
8.1 South America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
8.2 Brazil Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
8.3 Argentina Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Drugs for Non-small Cell Lung Cancer by Countries
9.1 Middle East & Africa Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
9.2 Saudi Arabia Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
9.3 UAE Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
9.4 Egypt Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
9.5 South Africa Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Drugs for Non-small Cell Lung Cancer Revenue and Market Share by Type (2015-2020)
10.2 Global Drugs for Non-small Cell Lung Cancer Market Forecast by Type (2019-2024)
10.3 Radiofrequency Ablation (RFA) Revenue Growth Rate (2015-2025)
10.4 Radiation Therapy Revenue Growth Rate (2015-2025)
10.5 Chemotherapy Revenue Growth Rate (2015-2025)
10.6 Targeted Therapies Revenue Growth Rate (2015-2025)
10.7 Immunotherapy Revenue Growth Rate (2015-2025)
11 Global Drugs for Non-small Cell Lung Cancer Market Segment by Application
11.1 Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Application (2015-2020)
11.2 Drugs for Non-small Cell Lung Cancer Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global Drugs for Non-small Cell Lung Cancer Market Size Forecast (2021-2025)
12.1 Global Drugs for Non-small Cell Lung Cancer Market Size Forecast (2021-2025)
12.2 Global Drugs for Non-small Cell Lung Cancer Market Forecast by Regions (2021-2025)
12.3 North America Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
12.4 Europe Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
12.6 South America Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Drugs for Non-small Cell Lung Cancer Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Drugs for Non-small Cell Lung Cancer by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Drugs for Non-small Cell Lung Cancer Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Drugs for Non-small Cell Lung Cancer Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 6. Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Major Business
Table 7. Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 8. Bristol-Myers Squibb SWOT Analysis
Table 9. Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 10. Bristol-Myers Squibb Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Apotex Corporate Information, Location and Competitors
Table 12. Apotex Drugs for Non-small Cell Lung Cancer Major Business
Table 13. Apotex Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2018-2019)
Table 14. Apotex SWOT Analysis
Table 15. Apotex Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 16. Apotex Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Sanofi Corporate Information, Location and Competitors
Table 18. Sanofi Drugs for Non-small Cell Lung Cancer Major Business
Table 19. Sanofi Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 20. Sanofi SWOT Analysis
Table 21. Sanofi Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 22. Sanofi Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. GlaxoSmithKline Corporate Information, Location and Competitors
Table 24. GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Major Business
Table 25. GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 26. GlaxoSmithKline SWOT Analysis
Table 27. GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 28. GlaxoSmithKline Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Amgen Corporate Information, Location and Competitors
Table 30. Amgen Drugs for Non-small Cell Lung Cancer Major Business
Table 31. Amgen Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 32. Amgen SWOT Analysis
Table 33. Amgen Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 34. Amgen Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Menarini Corporate Information, Location and Competitors
Table 36. Menarini Drugs for Non-small Cell Lung Cancer Major Business
Table 37. Menarini Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 38. Menarini SWOT Analysis
Table 39. Menarini Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 40. Menarini Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. CellAct Pharma Corporate Information, Location and Competitors
Table 42. CellAct Pharma Drugs for Non-small Cell Lung Cancer Major Business
Table 43. CellAct Pharma Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 44. CellAct Pharma SWOT Analysis
Table 45. CellAct Pharma Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 46. CellAct Pharma Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Alchemia Corporate Information, Location and Competitors
Table 48. Alchemia Drugs for Non-small Cell Lung Cancer Major Business
Table 49. Alchemia Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 50. Alchemia SWOT Analysis
Table 51. Alchemia Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 52. Alchemia Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Ziopharm Oncology Corporate Information, Location and Competitors
Table 54. Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Major Business
Table 55. Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 56. Ziopharm Oncology SWOT Analysis
Table 57. Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 58. Ziopharm Oncology Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. BioMarin Pharmaceutical Corporate Information, Location and Competitors
Table 60. BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Major Business
Table 61. BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 62. BioMarin Pharmaceutical SWOT Analysis
Table 63. BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 64. BioMarin Pharmaceutical Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. CytRx Corporate Information, Location and Competitors
Table 66. CytRx Drugs for Non-small Cell Lung Cancer Major Business
Table 67. CytRx Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 68. CytRx SWOT Analysis
Table 69. CytRx Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 70. CytRx Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. Fresenius Kabi Corporate Information, Location and Competitors
Table 72. Fresenius Kabi Drugs for Non-small Cell Lung Cancer Major Business
Table 73. Fresenius Kabi Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 74. Fresenius Kabi SWOT Analysis
Table 75. Fresenius Kabi Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 76. Fresenius Kabi Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Cerulean Pharma Corporate Information, Location and Competitors
Table 78. Cerulean Pharma Drugs for Non-small Cell Lung Cancer Major Business
Table 79. Cerulean Pharma Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 80. Cerulean Pharma SWOT Analysis
Table 81. Cerulean Pharma Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 82. Cerulean Pharma Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Hikma Pharmaceuticals Corporate Information, Location and Competitors
Table 84. Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Major Business
Table 85. Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 86. Hikma Pharmaceuticals SWOT Analysis
Table 87. Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 88. Hikma Pharmaceuticals Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Eli Lilly Corporate Information, Location and Competitors
Table 90. Eli Lilly Drugs for Non-small Cell Lung Cancer Major Business
Table 91. Eli Lilly Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 92. Eli Lilly SWOT Analysis
Table 93. Eli Lilly Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 94. Eli Lilly Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. Curis Corporate Information, Location and Competitors
Table 96. Curis Drugs for Non-small Cell Lung Cancer Major Business
Table 97. Curis Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 98. Curis SWOT Analysis
Table 99. Curis Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 100. Curis Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Cipla Corporate Information, Location and Competitors
Table 102. Cipla Drugs for Non-small Cell Lung Cancer Major Business
Table 103. Cipla Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 104. Cipla SWOT Analysis
Table 105. Cipla Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 106. Cipla Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Genentech Drugs for Non-small Cell Lung Cancer Type and Application
Table 108. Genentech Drugs for Non-small Cell Lung Cancer Major Business
Table 109. Genentech Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 110. Genentech SWOT Analysis
Table 111. Genentech Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 112. Genentech Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Exelixis Corporate Information, Location and Competitors
Table 114. Exelixis Drugs for Non-small Cell Lung Cancer Major Business
Table 115. Exelixis Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 116. Exelixis SWOT Analysis
Table 117. Exelixis Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 118. Exelixis Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 119. Cornerstone Pharmaceuticals Corporate Information, Location and Competitors
Table 120. Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Major Business
Table 121. Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 122. Cornerstone Pharmaceuticals SWOT Analysis
Table 123. Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 124. Cornerstone Pharmaceuticals Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 125. Hospira Corporate Information, Location and Competitors
Table 126. Hospira Drugs for Non-small Cell Lung Cancer Major Business
Table 127. Hospira Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 128. Hospira SWOT Analysis
Table 129. Hospira Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 130. Hospira Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 131. Ligand Pharmaceuticals Corporate Information, Location and Competitors
Table 132. Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Major Business
Table 133. Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 134. Ligand Pharmaceuticals SWOT Analysis
Table 135. Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 136. Ligand Pharmaceuticals Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 137. Kyowa Hakko Kirin Corporate Information, Location and Competitors
Table 138. Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Major Business
Table 139. Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 140. Kyowa Hakko Kirin SWOT Analysis
Table 141. Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 142. Kyowa Hakko Kirin Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 143. Intas Pharmaceuticals Corporate Information, Location and Competitors
Table 144. Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Major Business
Table 145. Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 146. Intas Pharmaceuticals SWOT Analysis
Table 147. Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 148. Intas Pharmaceuticals Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 149. Karyopharm Therapeutics Corporate Information, Location and Competitors
Table 150. Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Major Business
Table 151. Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Total Revenue (USD Million) (2017-2018)
Table 152. Karyopharm Therapeutics SWOT Analysis
Table 153. Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Product and Solutions
Table 154. Karyopharm Therapeutics Drugs for Non-small Cell Lung Cancer Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 155. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) by Players (2015-2020)
Table 156. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Players (2015-2020)
Table 157. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) by Regions (2015-2020)
Table 158. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Regions (2015-2020)
Table 159. North America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
Table 160. North America Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Table 161. Europe Drugs for Non-small Cell Lung Cancer Revenue (Million USD) by Countries (2015-2020)
Table 162. Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue (Million USD) by Countries (2015-2020)
Table 163. South America Drugs for Non-small Cell Lung Cancer Revenue by Countries (2015-2020)
Table 164. South America Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Table 165. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue (Million USD) by Countries (2015-2020)
Table 166. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Table 167. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) by Type (2015-2020)
Table 168. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Type (2015-2020)
Table 169. Global Drugs for Non-small Cell Lung Cancer Revenue Forecast by Type (2021-2025)
Table 170. Global Drugs for Non-small Cell Lung Cancer Revenue by Application (2015-2020)
Table 171. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Application (2015-2020)
Table 172. Global Drugs for Non-small Cell Lung Cancer Revenue Forecast by Application (2021-2025)
Table 173. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Drugs for Non-small Cell Lung Cancer Picture
Figure 2. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Type in 2019
Figure 3. Radiofrequency Ablation (RFA) Picture
Figure 4. Radiation Therapy Picture
Figure 5. Chemotherapy Picture
Figure 6. Targeted Therapies Picture
Figure 7. Immunotherapy Picture
Figure 8. Drugs for Non-small Cell Lung Cancer Revenue Market Share by Application in 2019
Figure 9. Hospitals Picture
Figure 10. Clinics Picture
Figure 11. Other Picture
Figure 12. Global Drugs for Non-small Cell Lung Cancer Revenue (USD Million) and Growth Rate (2015-2025)
Figure 13. North America Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Europe Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. South America Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 18. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (2015-2025)
Figure 19. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Players in 2019
Figure 20. Global Top 5 Players Drugs for Non-small Cell Lung Cancer Revenue Market Share in 2019
Figure 21. Global Top 10 Players Drugs for Non-small Cell Lung Cancer Revenue Market Share in 2019
Figure 22. Key Players Market Share Trend
Figure 23. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 24. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Regions (2015-2020)
Figure 25. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share by Regions in 2018
Figure 26. North America Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 27. Europe Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 28. Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 29. South America Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 30. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 31. North America Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Figure 32. North America Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries in 2019
Figure 33. USA Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 34. Canada Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 35. Mexico Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 36. Europe Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Figure 37. Europe Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries in 2019
Figure 38. Germany Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 39. UK Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 40. France Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 41. Russia Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 42. Italy Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 43. Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Figure 44. Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries in 2019
Figure 45. China Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 46. Japan Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 47. Korea Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 48. India Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 49. Southeast Asia Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 50. South America Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Figure 51. South America Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries in 2019
Figure 52. Brazil Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 53. Argentina Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 54. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries (2015-2020)
Figure 55. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue Market Share by Countries in 2019
Figure 56. Saudi Arabia Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 57. UAE Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 58. Egypt Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 59. South Africa Drugs for Non-small Cell Lung Cancer Revenue and Growth Rate (2015-2020)
Figure 60. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Type (2015-2020)
Figure 61. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Type in 2019
Figure 62. Global Drugs for Non-small Cell Lung Cancer Market Share Forecast by Type (2021-2025)
Figure 63. Global Radiofrequency Ablation (RFA) Revenue Growth Rate (2015-2020)
Figure 64. Global Radiation Therapy Revenue Growth Rate (2015-2020)
Figure 65. Global Chemotherapy Revenue Growth Rate (2015-2020)
Figure 66. Global Targeted Therapies Revenue Growth Rate (2015-2020)
Figure 67. Global Immunotherapy Revenue Growth Rate (2015-2020)
Figure 68. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Application (2015-2020)
Figure 69. Global Drugs for Non-small Cell Lung Cancer Revenue Share by Application in 2019
Figure 70. Global Drugs for Non-small Cell Lung Cancer Market Share Forecast by Application (2021-2025)
Figure 71. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 72. Global Clinics Revenue Growth Rate (2015-2020)
Figure 73. Global Other Revenue Growth Rate (2015-2020)
Figure 74. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 75. Global Drugs for Non-small Cell Lung Cancer Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 76. Global Drugs for Non-small Cell Lung Cancer Revenue Market Share Forecast by Regions (2021-2025)
Figure 77. North America Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
Figure 78. Europe Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
Figure 79. Asia-Pacific Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
Figure 80. South America Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
Figure 81. Middle East and Africa Drugs for Non-small Cell Lung Cancer Revenue Market Forecast (2021-2025)
Figure 82. Sales Channel: Direct Channel vs Indirect Channel



• 英文レポート名:Global Drugs for Non-small Cell Lung Cancer Market 2020 by Company, Regions, Type and Application, Forecast to 2025
• 日本語訳:非小細胞肺がん治療薬の世界市場 2020年:企業別・地域別・種類別・用途別市場予測
• レポートコード:D0804-15818お問い合わせ(見積依頼・ご注文・質問)